menu search

Merck discontinues some cancer drug development with china's sichuan kelun

Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drug...

October 23, 2023, 3:47 am

Eli lilly, novo nordisk to test weight loss drugs for children

Pharmaceutical manufacturers Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly planning to test their weight loss drugs for children six and older...

October 22, 2023, 11:00 am

Iovance biotherapeutics: testing shareholders' patience

Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on ...

October 22, 2023, 9:12 am

Olema oncology announces positive phase 2 monotherapy clinical study results for palazestrant

Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PF...

October 22, 2023, 6:55 am

Revolution medicines presents promising clinical activity and safety data from phase 1/1b trial of rmc-6236

Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) — Revolution Medicine...

October 22, 2023, 6:30 am

Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete re...

October 21, 2023, 3:31 pm

Precede biosciences unveils groundbreaking clinical data for its pioneering liquid biopsy platform at esmo 2023 and simultaneously publishes in nature medicine

Pivotal findings stem from Precede’s first-in-class platform in collaboration with Dana-Farber Cancer Institute Results underscore the immense poten...

October 21, 2023, 8:25 am

Xencor: a mid-stage clinical company with falling losses

Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and li...

October 20, 2023, 11:02 pm

Adial pharmaceuticals announces $4 million private placement priced at-the-market under nasdaq rules

CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a ...

October 20, 2023, 12:00 pm

Eli lilly plans diabetes drug trial for kids as young as 6 years - bloomberg

Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older wh...

October 20, 2023, 6:35 am

Allyx therapeutics to present phase 1 data for lead compound alx-001 at the 16th clinical trials on alzheimer’s disease meeting

Allyx’s lead compound, ALX-001, is a small molecule with unique mechanism of action at mGluR5, to protect and preserve synapses in neurodegenerative...

October 19, 2023, 8:05 pm

Terns pharmaceuticals to participate in upcoming investor conferences

FOSTER CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a ...

October 19, 2023, 8:05 pm

Adial pharmaceuticals to present at the fall foliage microcap rodeo conference on october 25th

CHARLOTTESVILLE, VA / ACCESSWIRE / October 19, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a ...

October 19, 2023, 12:00 pm

Excision biotherapeutics announces presentation of interim clinical data for ebt-101 in latent hiv at upcoming european society of gene and cell therapy (esgct) 2023 annual congress

SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biot...

October 19, 2023, 11:50 am

Volitionrx highlights study demonstrating nu.q nets is promising biomarker for septic shock

VolitionRx (NYSE-A:VNRX) has highlighted a recently published paper in Annals of Intensive Care which shows the company's Nu.Q NETs test is a promisin...

October 19, 2023, 9:32 am

Maia biotechnology to present preliminary safety and efficacy data from thio-101 phase 2 clinical trial at european society for medical oncology congress 2023

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 ...

October 19, 2023, 8:35 am

Biogen to present new data at the clinical trials on alzheimer's disease (ctad) 2023 meeting

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upc...

October 19, 2023, 7:30 am

Verona pharma to report third quarter 2023 financial results and provide corporate update

LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a ...

October 19, 2023, 2:00 am

Cytomx therapeutics presents preclinical profile of epcam-directed antibody drug conjugate cx-2051 at 2023 world adc conference

– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor...

October 18, 2023, 8:30 pm


Search within

Pages Search Results: